Video

Dr. Zelenetz on Progress Made in MCL Treatment

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses progress made in mantle cell lymphoma (MCL) treatment.

MCL is a relatively rare disease, says Zelenetz. The typical oncologist in the United States who specializes in lymphoma will see a new diagnosis of MCL every 1 to 2 years; it is an uncommon disease with only about 4,000 cases per year reported in the United States. As a result, advances in lymphoma treatment have lagged behind that of other cancers.

However, important drugs have been approved in this space, Zelenetz adds. Several years ago, bortezomib (Velcade) was approved for the treatment of patients with relapsed/refractory MCL. The agent has activity, but because of the treatment-emergent neuropathy that has been reported, it is not widely used. Lenalidomide (Revlimid) also received regulatory approval for use in these patients, and when used in combination with rituximab (Rituxan), it is highly active, concludes Zelenetz.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Manali Kamdar, MD, of University of Colorado Anschutz School of Medicine
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Leo I. Gordon, MD